Shouldn ’t VIVUS Raise Capital Now? (VVUS)
While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers after VIVUS, Inc. (NASDAQ: VVUS) has basically doubled on news of Qnexa getting a recommendation for approval from a FDA panel…
If you were the CEO or CFO of VIVUS, wouldn’t you immediately go out and raise capital now?
Our take is not just “yes” but a resounding yes. With $150 million or so in net tangible assets as of September 30, 2011, with a ten-year history, and for many more reasons, this...
Source: BioHealth Investor - February 23, 2012 Category: Pharmaceuticals Authors: 247admin Tags: Diabetes fda Financial Heart obesity Secondary Offering VVUS Source Type: news
Implosion Analysis For Targacept … What Lies Ahead? (TRGT, AZN)
Tuesday has been an awful day for shareholders of Targacept Inc. (NASDAQ: TRGT). The company shares lost more than half of their value on news that initial test results from the Phase III antidepressant (TC-5214) failed to meet their endpoints in treating major depressive disorder. Targacept is covered under a co-development pact with AstraZeneca PLC (NYSE: AZN) in the United Kingdom and this is supposed to be an add-on treatment for patients where primary treatment was not adequate.
Effectively, this was the first of four Phase III trials and more data on all of the results should come by the first half of 2012. Wha...
Source: BioHealth Investor - November 8, 2011 Category: Pharmaceuticals Authors: 247admin Tags: Depression R&D AZN TRGT Source Type: news
Unusual Analyst Upgrade & Endorsement for Cell Therapeutics (CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is a controversial stock in the field of cancer and the company is still aiming for a 2012 debut market launch for its pixantrone drug candidate. In the last couple of weeks it had reported more positive data and the FDA had earlier this year noted that pixantrone would need a review using a new panel of independent radiologists. Pixantrone is to be a new treatment for non-Hodgkin Lymphoma.
Â
This morning we saw a very unlikely and very unusual support or endorsement of Cell Therapeutics. This came from Zacks Investment Research where the outfit was called The Bull of The Day.Â...
Source: BioHealth Investor - October 13, 2011 Category: Pharmaceuticals Authors: 247admin Tags: analyst calls Cancer fda R&D Research CTIC Source Type: news
